Fixed-Dose Combination of Abacavir, Lamivudine and Zidovudine for HIV Therapy

Abstract

Triple-nucleoside therapy with abacavir (ABV)/lamivudine (3TC)/zidovudine (ZDV) combination tablets provides simple, nonfood-dependent, twice-daily, well-tolerated therapy with the potential to improve long-term adherence at a lower cost than other triple-drug regimens. Of all the triple nucleoside reverse transcriptase inhibitor combinations currently available, ABV/3TC/ZDV is most extensively studied. Although ABV/3TC/ZDV is possibly less potent than other treatment options when used alone, other attributes described in this review make it an attractive option for selected patients. This combination spares the use of protease inhibitors and their associated side effects, such as metabolic abnormalities, which may contribute to premature cardiovascular disease. Furthermore, by using only one drug class, it may maintain a greater number of future treatment options. Data from ongoing clinical trials may result in expanding the use of ABV/3TC/ZDV as a component of multidrug, highly active antiretroviral therapy regimens.

Keywords: :

• abacavir
• efficacy
• hypersensitivity
• lamivudine
• safety
• Trizivir
• zidovudine

Acknowledgements

Thanks to Rob Camp, Treatment Action Group (NY, USA) for reading this manuscript with a critical eye.

Additional information

Funding

Thanks to Rob Camp, Treatment Action Group (NY, USA) for reading this manuscript with a critical eye.